AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30985210 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidemia
Number of subjects: 1741
Study 30985210 — intervention group
Group type: EXPERIMENTAL
Intervention: Alactic base excess
Number of subjects: 1741
Study 30985210 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid balance
Number of subjects: 1741
Study 27820728 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-times stretching treatment
Number of subjects: 50
Study 27820728 — intervention group
Group type: COMPARATOR
Intervention: 50-times stretching treatment
Number of subjects: 50
Study 24575727 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-labels
Number of subjects: 300
Study 24575727 — intervention group
Group type: COMPARATOR
Intervention: No-labels
Number of subjects: 300
Study 24575727 — intervention group
Group type: EXPERIMENTAL
Intervention: Kcal-labels
Number of subjects: 300
Study 23928892 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 253
Study 23928892 — intervention group
Group type: COMPARATOR
Intervention: White-light endoscopy (WLE)
Number of subjects: 253
Study 22403970 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic inhalation of isopropyl alcohol (IPA) vapors with IV ondansetron
Number of subjects: 76
Study 22403970 — intervention group
Group type: COMPARATOR
Intervention: IV ondansetron alone
Number of subjects: 76
Study 19017751 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Number of subjects: 3548
Study 19017751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3548
Study 19017751 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 3548
Study 17524288 — intervention group
Group type: EXPERIMENTAL
Intervention: OraSure oral fluid testing
Number of subjects: 354
Study 15455744 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital subtraction radiography
Number of subjects: 18
Study 15455744 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiographic interpretation
Number of subjects: 18
Study 11266197 — intervention group
Group type: EXPERIMENTAL
Intervention: Middleoxic (PO2=500+/‐50 mmHg) reperfusion
Number of subjects: 21
Study 11266197 — intervention group
Group type: EXPERIMENTAL
Intervention: More physiologic (PO2=200‐250 mmHg) cardiopulmonary bypass
Number of subjects: 21
Study 11266197 — intervention group
Group type: COMPARATOR
Intervention: Hyperoxic (PO2=450‐550 mmHg) cardiopulmonary bypass
Number of subjects: 21
Study 9791322 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood clarity
Number of subjects: 0
Study 9791322 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms and pessimism
Number of subjects: 0
Study 7987882 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/day simvastatin
Number of subjects: 281
Study 7987882 — intervention group
Group type: COMPARATOR
Intervention: 10 mg/day pravastatin
Number of subjects: 281
Study 7987882 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day simvastatin
Number of subjects: 281
Study 7987882 — intervention group
Group type: EXPERIMENTAL
Intervention: simvastatin
Number of subjects: 281
Study 7987882 — intervention group
Group type: COMPARATOR
Intervention: pravastatin
Number of subjects: 281
Study 2547465 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous doses of lisinopril
Number of subjects: 3
Study 2547465 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral doses of lisinopril (10 daily doses, q24h)
Number of subjects: 3
Study 5302328 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-cell cholera vaccine, 0.5 ml dose
Number of subjects: 0
Study 5302328 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified Ogawa antigen, 100 mug dose
Number of subjects: 0
Study 5302328 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-cell cholera vaccine, 0.4 ml dose
Number of subjects: 0
Study 5302328 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-cell cholera vaccine
Number of subjects: 0
Study 31877361 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-session asthma self-management intervention
Number of subjects: 189
Study 31209698 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathe Right Nasal Strips (BRNS)
Number of subjects: 270
Study 31209698 — intervention group
Group type: COMPARATOR
Intervention: Placebo strip
Number of subjects: 270
Study 29151315 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/day oral iron for 3 months
Number of subjects: 90
Study 29151315 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo for 3 months
Number of subjects: 90
Study 26496720 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Level Laser (LLL) applied at the point of greatest pain, 10 patients, 12 sessions, 3 times per week.
Number of subjects: 30
Study 26496720 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Level Laser (LLL) applied at pre-established points in the affected muscles, 10 patients, 12 sessions, 3 times per week.
Number of subjects: 30
Study 26496720 — intervention group
Group type: COMPARATOR
Intervention: Placebo group, 10 patients, 12 sessions, 3 times per week.
Number of subjects: 30
Study 23680766 — intervention group
Group type: EXPERIMENTAL
Intervention: agalsidase alfa (0.2 mg/kg every other week for 12 months)
Number of subjects: 73
Study 23680766 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 73
Study 23680766 — intervention group
Group type: EXPERIMENTAL
Intervention: agalsidase alfa
Number of subjects: 73
Study 22012809 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of tranexamic acid (loading dose of 500 mg before surgery followed by continuous infusion of 250 mg/h during surgery)
Number of subjects: 200
Study 22012809 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 200
Study 22012809 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of tranexamic acid
Number of subjects: 200
Study 22012809 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion of tranexamic acid and placebo
Number of subjects: 200
Study 19691851 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate and amodiaquine fixed dose combination (FDC)
Number of subjects: 140
Study 19691851 — intervention group
Group type: COMPARATOR
Intervention: Artesunate and amodiaquine given in separate tablets
Number of subjects: 140
Study 17005447 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed EMF emitted by a mobile phone for 30 minutes
Number of subjects: 16
Study 17005447 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure (control)
Number of subjects: 16
Study 15747942 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based nurses visiting patients in the home as part of shared care.
Number of subjects: 0
Study 15747942 — intervention group
Group type: COMPARATOR
Intervention: Previous phase without monitoring facilities at the patient's home.
Number of subjects: 0
Study 11028740 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 20
Study 11028740 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 20
Study 9118699 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐5‐hydroxytryptophan (L‐5‐HTP), 0.4 mg/kg
Number of subjects: 11
Study 9118699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 9118699 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP-treated OSA patients
Number of subjects: 11
Study 8100625 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% brimonidine before and after ALT
Number of subjects: 232
Study 8100625 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine before but vehicle after ALT
Number of subjects: 232
Study 8100625 — intervention group
Group type: EXPERIMENTAL
Intervention: Vehicle before but brimonidine after ALT
Number of subjects: 232
Study 8100625 — intervention group
Group type: COMPARATOR
Intervention: Vehicle at both times
Number of subjects: 232
Study 3558443 — intervention group
Group type: EXPERIMENTAL
Intervention: Siliconized tetrafluorethylene cannula
Number of subjects: 30
Study 3558443 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparinized tetrafluorethylene cannula
Number of subjects: 30
Study 3558443 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorethylenpropylene cannula
Number of subjects: 30
Study 29996844 — intervention group
Group type: COMPARATOR
Intervention: Parasite clearance profiles
Number of subjects: 154
Study 28581398 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-escalated external beam (DE‐EBRT) boost
Number of subjects: 357
Study 28581398 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose-rate prostate brachytherapy (LDR‐PB) boost
Number of subjects: 357
Study 26621252 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medication at baseline
Number of subjects: 4393
Study 26621252 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medication at follow up
Number of subjects: 4393
Study 26621252 — intervention group
Group type: EXPERIMENTAL
Intervention: CESD-10 scores at follow-up
Number of subjects: 4393
Study 26621252 — intervention group
Group type: EXPERIMENTAL
Intervention: CESD-10 scores of ten or more at baseline
Number of subjects: 4393
Study 24089493 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS(anodal) over left IFG
Number of subjects: 36
Study 24089493 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS(anodal) over left IPC
Number of subjects: 36
Study 24089493 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 36
Study 21440468 — intervention group
Group type: EXPERIMENTAL
Intervention: Ski cap only
Number of subjects: 20
Study 21440468 — intervention group
Group type: EXPERIMENTAL
Intervention: Ski helmet only
Number of subjects: 20
Study 21440468 — intervention group
Group type: EXPERIMENTAL
Intervention: Ski cap and ski goggles
Number of subjects: 20
Study 21440468 — intervention group
Group type: EXPERIMENTAL
Intervention: Ski helmet and ski goggles
Number of subjects: 20
Study 21440468 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 20
Study 19146601 — intervention group
Group type: EXPERIMENTAL
Intervention: Capryloyl salicylic acid (LHA) peel (5-10%)
Number of subjects: 50
Study 19146601 — intervention group
Group type: COMPARATOR
Intervention: Glycolic acid (GA) peel (20-50%)
Number of subjects: 50
Study 16464637 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (N=8)
Number of subjects: 20
Study 16464637 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (N=12)
Number of subjects: 20
Study 16464637 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study 14500473 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of MCC-TT vaccine
Number of subjects: 586
Study 14500473 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of MCC-TT vaccine
Number of subjects: 586
Study 14500473 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of MCC-TT vaccine
Number of subjects: 586
Study 10710869 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed X-ray densitometry (CXD) measurement of metacarpal bone mineral density (mBMD) and metacarpal index (MCI)
Number of subjects: 1182
Study 10710869 — intervention group
Group type: COMPARATOR
Intervention: Normal young population
Number of subjects: 1182
Study 8992904 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium (0.5 mg/kg)
Number of subjects: 108
Study 8992904 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium (0.6 mg/kg)
Number of subjects: 108
Study 8992904 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium (0.1 mg/kg)
Number of subjects: 108
Study 8992904 — intervention group
Group type: COMPARATOR
Intervention: Control (younger groups 18-50 and 51-64)
Number of subjects: 108
Study 8992904 — intervention group
Group type: EXPERIMENTAL
Intervention: All relaxants (Atracurium, Rocuronium, Vecuronium)
Number of subjects: 108
Study 8992904 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 108
Study 1394812 — intervention group
Group type: COMPARATOR
Intervention: Intravesical thio-TEPA at 30 mg/30 ml physiological saline, instilled 32 times over 2 years (group T)
Number of subjects: 153
Study 1394812 — intervention group
Group type: COMPARATOR
Intervention: Oral UFT given at 1296 mg/day for 2 years (group U)
Number of subjects: 153
Study 1394812 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic treatment (group C)
Number of subjects: 153
Study 1394812 — intervention group
Group type: COMPARATOR
Intervention: Intravesical thio-TEPA (group T)
Number of subjects: 153
Study 1394812 — intervention group
Group type: COMPARATOR
Intervention: Oral UFT (group U)
Number of subjects: 153
Study 1394812 — intervention group
Group type: COMPARATOR
Intervention: Group C
Number of subjects: 153
Study 1394812 — intervention group
Group type: COMPARATOR
Intervention: Group U
Number of subjects: 153
Study 1394812 — intervention group
Group type: COMPARATOR
Intervention: Group T
Number of subjects: 153
Study 3900847 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocopherol treatment (early parenteral tocopherol given from day one)
Number of subjects: 287
Study 3900847 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (control group)
Number of subjects: 287
Study 3900847 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocopherol treatment
Number of subjects: 287
Study 30530284 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of hemoglobin
Number of subjects: 3881
Study 30530284 — intervention group
Group type: COMPARATOR
Intervention: Lowest quartile of hemoglobin
Number of subjects: 3881
Study 30256746 — intervention group
Group type: EXPERIMENTAL
Intervention: New skin protectant
Number of subjects: 21
Study 30256746 — intervention group
Group type: COMPARATOR
Intervention: Other 3 products
Number of subjects: 21
Study 26891156 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic simulator
Number of subjects: 54
Study 26891156 — intervention group
Group type: COMPARATOR
Intervention: Cadaver
Number of subjects: 54
Study 24142966 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS)
Number of subjects: 139
Study 24142966 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofraction stereotactic radiotherapy (HSRT)
Number of subjects: 139
Study 24142966 — intervention group
Group type: COMPARATOR
Intervention: Conventional fraction stereotactic radiotherapy (CSRT)
Number of subjects: 139
Study 22133776 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 499
Study 22133776 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide 100 mg/day
Number of subjects: 499
Study 22133776 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide 200 mg/day
Number of subjects: 499
Study 22133776 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide 400 mg/day
Number of subjects: 499
Study 22133776 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (all doses)
Number of subjects: 499
Study 19840063 — intervention group
Group type: EXPERIMENTAL
Intervention: Xanthigen-600/2.4 mg (300 mg PSO + 300 mg brown seaweed extract containing 2.4 mg fucoxanthin)
Number of subjects: 151
Study 19840063 — intervention group
Group type: EXPERIMENTAL
Intervention: Fucoxanthin (> 2.4 mg)
Number of subjects: 151
Study 19840063 — intervention group
Group type: EXPERIMENTAL
Intervention: Xanthigen-400/1.6 mg (200 mg PSO + 200 mg brown seaweed extract containing 1.6 mg fucoxanthin)
Number of subjects: 151
Study 17555170 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdental wooden wedge (Hawe‐Neos)
Number of subjects: 27
Study 17555170 — intervention group
Group type: EXPERIMENTAL
Intervention: Separation ring (Composi‐Tight Gold)
Number of subjects: 27
Study 17555170 — intervention group
Group type: COMPARATOR
Intervention: Wooden wedge combined with separation ring (Composi‐Tight Gold)
Number of subjects: 27
Study 15361517 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive subjects
Number of subjects: 3
Study 15361517 — intervention group
Group type: COMPARATOR
Intervention: Normotensive subjects
Number of subjects: 3
Study 15361517 — intervention group
Group type: COMPARATOR
Intervention: Controlled hypertensive subjects
Number of subjects: 3
Study 15361517 — intervention group
Group type: COMPARATOR
Intervention: Uncontrolled hypertensive subjects
Number of subjects: 3
Study 16982237 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg)
Number of subjects: 217
Study 16982237 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (1000 mg)
Number of subjects: 217
Study 16982237 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (100 mg)
Number of subjects: 217
Study 16982237 — intervention group
Group type: COMPARATOR
Intervention: Control group (no suppository treatment)
Number of subjects: 217
Study 10371772 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidemiological study of Alzheimer's disease
Number of subjects: 4134
Study 8878773 — intervention group
Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunts
Number of subjects: 25
Study 8878773 — intervention group
Group type: COMPARATOR
Intervention: Paracentesis
Number of subjects: 25
Study 1999775 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-tetanus toxoid (PRP-T) in Pennsylvania
Number of subjects: 313
Study 1999775 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-outer membrane protein (OMP)
Number of subjects: 313
Study 1999775 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-D in Dallas
Number of subjects: 313
Study 1999775 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib oligosaccharide-CRM197 (HbOC)
Number of subjects: 313
Study 1999775 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with prevaccination antibody > 0.15 microgram/ml
Number of subjects: 313
Study 1999775 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with prevaccination antibody ≤ 0.15 microgram/ml
Number of subjects: 313
Study 6141317 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 34
Study 6141317 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 34
Study 6141317 — intervention group
Group type: COMPARATOR
Intervention: Beta-blocker group (Atenolol)
Number of subjects: 34
Study 6141317 — intervention group
Group type: COMPARATOR
Intervention: Diuretic group (Hydrochlorothiazide)
Number of subjects: 34
Study 31568142 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive measures including Intelligence Quotient tests, Color Trails Tests, and Beery-Buktenica Developmental Test of Visual-Motor Integration conducted semiannually over 3-6 years.
Number of subjects: 0
Study 31568142 — intervention group
Group type: COMPARATOR
Intervention: Lowest scoring trajectory group characteristics
Number of subjects: 0
Study 29431146 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment plus hyperbaric oxygen therapy (HBOT)
Number of subjects: 60
Study 29431146 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment only
Number of subjects: 60
Study 26353751 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed Tc‐99m tetrofosmin tracer dose
Number of subjects: 148
Study 26353751 — intervention group
Group type: EXPERIMENTAL
Intervention: Body-weight-dependent protocol
Number of subjects: 148
Study 24612764 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic adjustment (AA)
Number of subjects: 16
Study 24612764 — intervention group
Group type: COMPARATOR
Intervention: Fixed termination criterion
Number of subjects: 16
Study 22864525 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic gadolinium injection (gadolinium‐diethylene‐triamine pentaacetic acid diluted eightfold with saline)
Number of subjects: 39
Study 22864525 — intervention group
Group type: COMPARATOR
Intervention: Intravenous gadolinium injection (double dose of gadoteridol (0.5 mmol/ml); 0.2 mmol/kg body weight)
Number of subjects: 39
Study 22864525 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic gadolinium injection
Number of subjects: 39
Study 22864525 — intervention group
Group type: COMPARATOR
Intervention: Intravenous gadolinium injection
Number of subjects: 39
Study 21330796 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid simulation (HYB) with patient-actor
Number of subjects: 24
Study 21330796 — intervention group
Group type: COMPARATOR
Intervention: Small-group tutorial (SGT)
Number of subjects: 24
Study 21330796 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (HYB and SGT)
Number of subjects: 24
Study 17475531 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII) with bolus optimization and sulfonylurea at bedtime
Number of subjects: 59
Study 17475531 — intervention group
Group type: COMPARATOR
Intervention: Continuous subcutaneous insulin infusion (CSII) with basal rate optimization and sulfonylurea before meals
Number of subjects: 59
Study 16091670 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise (moderate intensity dynamic exercise, 30-40 min, 4-5 sessions per week)
Number of subjects: 0
Study 16091670 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (addition to pharmacological therapy)
Number of subjects: 0
Study 12041718 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol 3350 (10 g/m2/day)
Number of subjects: 37
Study 12041718 — intervention group
Group type: COMPARATOR
Intervention: Lactulose (1.3 g/kg/d divided twice daily up to 20 g)
Number of subjects: 37
Study 12041718 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol 3350
Number of subjects: 37
Study 12041718 — intervention group
Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 37
Study 10066991 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative-symptom group
Number of subjects: 0
Study 10066991 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 10066991 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive-symptom group
Number of subjects: 0
Study 7478050 — intervention group
Group type: EXPERIMENTAL
Intervention: COF (modified Fick method using mixed venous O2 content)
Number of subjects: 10
Study 7478050 — intervention group
Group type: EXPERIMENTAL
Intervention: COFra (modified Fick method using central venous O2 content)
Number of subjects: 10
Study 7478050 — intervention group
Group type: COMPARATOR
Intervention: COTD (thermodilution technique, gold standard)
Number of subjects: 10
Study 31088342 — intervention group
Group type: EXPERIMENTAL
Intervention: Real dual-tDCS
Number of subjects: 21
Study 31088342 — intervention group
Group type: COMPARATOR
Intervention: Sham dual-tDCS
Number of subjects: 21